methyl 2-(4-(cyanomethyl)phenyl)acetate | 193290-61-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-(cyanomethyl)phenyl)acetate
• 英文别名: (4-cyanomethyl-phenyl)-acetic acid methyl ester；methyl 2-[4-(cyanomethyl)phenyl]acetate
• CAS: 193290-61-8
• 化学式: C₁₁H₁₁NO₂
• mdl: MFCD09924370
• 分子量: 189.214
• InChiKey: GTZIKOIEWPFOKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  312.9±22.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-(cyanomethyl)phenyl)acetate 在 palladium on activated charcoal 盐酸 、 lithium hydroxide 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 25.0 ℃ 、482.63 kPa 条件下， 生成 N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-2-[4-[2-(methanesulfonamido)ethyl]phenyl]-N-methylacetamide
  参考文献：
  名称：

  Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

  摘要：

  Some K opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 mu M) while displaying high affinity toward the cloned human K opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.020
• 作为产物：
  描述：

  4-(溴甲基)苯乙酸 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 2-(4-(cyanomethyl)phenyl)acetate
  参考文献：
  名称：

  Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

  摘要：

  Some K opioid receptor agonists of the arylacetamide class, for example, ICI 199441 (1), were found to strongly inhibit the activity of cytochrome P450 2D6 (CYP2D6) (1: CYP2D6 IC50 = 26 nM). Certain analogs bearing a substituted sulfonylamino group, for example, 13, were discovered to have significantly reduced CYP2D6 inhibitory activity (13: CYP2D6 IC50 > 10 mu M) while displaying high affinity toward the cloned human K opioid receptor, good kappa/delta and kappa/mu selectivity, and potent in vitro and in vivo agonist activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.020

文献信息

• [EN] HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND<br/>[FR] COMPOSÉ INDUISANT LA DÉGRADATION DE LA HMG-COA RÉDUCTASE
  申请人：UPPTHERA

  公开号：WO2021201577A1

  公开（公告）日：2021-10-07

  The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention also relates a method for preparing the compounds, and a method for degradation of HMG-CoA reducatase using the compounds, as well as use for prevention or treatment of HMG-CoA reductase related diseases using the compounds.

  本发明涉及HMG-CoA还原酶降解诱导化合物。具体而言，本发明涉及一种双功能化合物，其中HMG-CoA还原酶结合基团和E3泛素连接酶结合基团通过化学连接剂连接。本发明还涉及一种制备这些化合物的方法，以及使用这些化合物降解HMG-CoA还原酶的方法，以及使用这些化合物预防或治疗与HMG-CoA还原酶相关疾病的方法。
• Sulfonylamino phenylacetamide derivatives and methods of their use
  申请人：——

  公开号：US20040254156A1

  公开（公告）日：2004-12-16

  Sulfonylamino phenylacetamide derivatives of the general formula 1 are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to &kgr; opioid receptors; (2) display good opioid receptor selectivity of &kgr; versus &mgr; and &kgr; versus &dgr;; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.

  揭示了通式1的磺酰氨基苯乙酰胺衍生物。还公开了含有这些化合物的药物组合物和它们的使用方法。在某些实施例中，本发明的化合物最好具有以下特征：(1) 与κ阿片受体结合的亲和力高；(2) 在κ与μ受体以及κ与δ受体之间显示良好的阿片受体选择性；以及(3) 不显著抑制细胞色素P450酶的活性，特别是CYP2D6、CYP2C9和CYP3A4。
• NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION
  申请人：LABORATORIOS MENARINI S.A.

  公开号：EP0874826A1

  公开（公告）日：1998-11-04
• US6992193B2
  申请人：——

  公开号：US6992193B2

  公开（公告）日：2006-01-31
• [EN] NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION<br/>[FR] QUINOLEINES DE NAPHTALENE AYANT UNE ACTION ANTAGONISTE AUX LEUCOTRIENES
  申请人：LABORATORIOS MENARINI S.A.

  公开号：WO1997024331A1

  公开（公告）日：1997-07-10

  (EN) The present invention relates to novel naphthalene quinolines of formula (I), wherein the substituent containing A is bound to the 6- or 7-position of the 2-naphthol system; -R1, R2, R6 are independently hydrogen, fluorine, chlorine, bromine, -OCH3 or (C1-C4)-alkyl; R3 is hydrogen or methyl; R4, R5 are independently hydrogen, -OH, -NH2, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylamino, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylcarbonylamino, (C1-C4)-alkoxycarbonylalkyl, carbamoyl, carbamoylalkyl, N,N-dialkylcarbamoylalkyl; -A- is a diradical -O-, -S-, -SO2-, -SO-, -SO2NR7- or -NR7SO2- wherein R7 is hydrogen or (C1-C4)-alkyl; B is a sulfur or oxygen atom or a -SO2- or -SO- group or a single bond; D is a 5-tetrazolyl or -COOR8 group, wherein R8 is hydrogen, a (C1-C4)-alkyl; or a phenylalkyl group of less than 10 carbon atoms; m is an integer from 0 to 4; n and p are integers from 0 to 6, with the proviso that n + p is less or equal to 6. Said compounds show a leukotriene-antagonistic activity, and they are valuable as anti-inflammatory and antiallergic medicaments or in the treatment of cardiovascular diseases.(FR) La présente invention se rapporte à de nouvelles quinoléines de napthtalène de la formule (I) dans laquelle le substituant contenant A est lié à la position 6- ou 7- du système 2-naphthol; -R1, R2, R6 représentent indépendamment hydrogène, fluore, chlore, brome, -OCH3 ou (C1-C4)-alkyl; R3 représente hydrogène ou méthyle; R4, R5 représentent indépendamment hydrogène, -OH, -NH2, (C1-C4)-alkyle, (C1-C4)-alkoxy, (C1-C4)-alkylamino, (C1-C4)-alkoxy-carbonyl, (C1-C4)-alkylcarbonylamino, (C1-C4)-alkoxy-carbonylalkyle, carbamoyle, carbamoylalkyle, N, N-dialkylcarbamoyalkyle; -A- représente un diradical -O-, -S-, -SO2-, -SO-, -SO2NR7- ou -NR7SO2- où R7 représente hydrogène ou (C1-C4)-alkyle; B est un atome de soufre ou d'oxygène ou un groupe -SO2-, -SO- ou une liaison simple; D représente un groupe 5-tetrazolyl ou -COOR8, dans lequel R8 représente hydrogène, un (C1-C4)-alkyl ou un groupe phénylalkyle possédant moins de 10 atomes de carbone; m est un nombre entier compris en 0 et 4; n et p sont des nombres entiers compris 0 et 6, à condition que n + p soit inférieur ou égal à 6. Ces composés présentent une activité antagoniste aux leucotriènes et ils présentent un intérêt comme médicaments anti-inflammatoires et anti-allergiques, ou dans le traitement de maladies cardiovasculaires.